Revolutionizing Synthetic Biology
Biomatter, a pioneer in enzyme design, has secured €6.5 million in seed funding, co-led by Inventure and UVC Partners. This investment marks a significant milestone in the application of generative AI to synthetic biology, paving the way for groundbreaking advancements in the field.
Key Developments and Achievements
- In 2019, Biomatter created the first fully functional enzymes using generative AI, published in Nature Machine Intelligence
- The company’s Intelligent Architecture™ platform enables the creation of entirely new enzymes without natural templates
- Major global players like Thermo Fisher Scientific, BASF, and Neogen are already utilizing Biomatter’s technology
- The platform has reduced enzyme development cycles from years to weeks
- Collaboration with Kirin has led to a novel enzyme-based method for producing Human Milk Oligosaccharides (HMOs)
Transforming Industries and Addressing Global Challenges
Biomatter’s innovative approach to enzyme design has far-reaching implications across multiple industries, including chemical biomanufacturing, agriculture, food, and life sciences. As the global population grows, the demand for innovative solutions in medicine, sustainable chemical manufacturing, and efficient food production intensifies. Enzymes play a crucial role in this transformation, and Biomatter’s technology offers a scalable solution to the challenges of traditional enzyme engineering methods.
By breaking free from the constraints of natural evolution, Biomatter’s platform allows for the creation of enzymes tailored to specific industrial needs. This capability has the potential to revolutionize various sectors and contribute to addressing pressing global challenges, such as sustainable chemical production and improved infant nutrition.
